Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: angiogenesis inhibitors - AbbVie/Pharmacopeia

Drug Profile

Research programme: angiogenesis inhibitors - AbbVie/Pharmacopeia

Alternative Names: PS388023; PS680648; PS780035

Latest Information Update: 19 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Developer AbbVie; Ligand Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Benzimidazoles; Isoquinolines; Pyrimidines; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Eye disorders

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 12 Jul 2005 This programme has been licensed to Allergan worldwide for the treatment of eye disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top